Production of enantiomerically enriched chiral carbinols using whole-cell biocatalyst

Basit Öğe Kaydı
dc.authoridKalay, Erbay/0000-0002-4656-8254
dc.contributor.authorBaydas, Yasemin
dc.contributor.authorKalay, Erbay
dc.contributor.authorSahin, Engin
dc.date.accessioned2024-10-04T18:52:43Z
dc.date.available2024-10-04T18:52:43Z
dc.date.issued2022
dc.departmentBayburt Üniversitesien_US
dc.description.abstractBiocatalytic asymmetric reduction of ketone is an efficient method for the production of chiral carbinols. The study indicates selective bioreduction of different ketones (1-8) to their respective (R)-alcohols (1a-8a) in low to high selectivity (0- >99%) with good yields (11-96%). In this work, whole-cell of Lactobacillus kefiri P2 catalysed enantioselective reduction of various prochiral ketones was investigated. (R)-4-Phenyl-2-butanol 2a, which is used as a precursor to antihypertensive agents and spasmolytics (anti-epileptic agents), was obtained using L kefiri P2 in 99% conversion and 91% enantiomeric excess (ee). Moreover, bioreduction of 2-methyl-1-phenylpropan-1-one substrate 8, containing a branched alkyl chain and difficult to asymmetric reduction with chemical catalysts as an enantioselective, to (R)-2-methyl-1-phenylpropan-1-ol (8a) in enantiomerically pure form was carried out in excellent yield (96%). The gram-scale production was carried out, and 9.70 g of (R)-2-methyl-1-phenylpropan-1-ol (8a) in enantiomerically pure form was obtained in 96% yield. Also especially, the yield and gram scale of (R)-2-methyl-1-phenylpropan-1-ol (8a) synthesised through catalytic asymmetric reduction using the biocatalyst was the highest report so far. The efficiency of L kefiri P2 for the conversion of the substrates and ee of products were markedly influenced by the steric factors of the substrates. This is a cheap, clean and eco-friendly process for production of chiral carbinols compared to chemical processes.en_US
dc.identifier.doi10.1080/10242422.2020.1837782
dc.identifier.endpage37en_US
dc.identifier.issn1024-2422
dc.identifier.issn1029-2446
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85093115475en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage29en_US
dc.identifier.urihttps://doi.org/10.1080/10242422.2020.1837782
dc.identifier.urihttp://hdl.handle.net/20.500.12403/3629
dc.identifier.volume40en_US
dc.identifier.wosWOS:000581884800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBiocatalysis and Biotransformationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAsymmetric reductionen_US
dc.subjectwhole-cell biocatalystsen_US
dc.subjectLactobacillus kefirien_US
dc.subjectchiral carbinolen_US
dc.subjectbiocatalytic transformationen_US
dc.titleProduction of enantiomerically enriched chiral carbinols using whole-cell biocatalysten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu